Clinical Trial: 68Ga-XHER2 PET/CT for HER2 Assessment

U.S., Oct. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07885436) titled '68Ga-XHER2 PET/CT for HER2 Assessment' on Oct. 14.

Brief Summary: The objective of this study is to evaluate the feasibility of 68Ga-XHER2 PET/CT as a noninvasive imaging approach for assessing HER2 expression in patients with solid tumors and to investigate the correlation between tracer uptake and pathological HER2 expression.

Study Start Date: Oct. 22

Study Type: INTERVENTIONAL

Condition: Solid Tumor (Excluding CNS) HER2 PET / CT

Intervention: DRUG: 68Ga-XHER2 PET/CT

Each participant will receive a single intravenous injection of 68Ga-XHER2, a novel HER2-targeted PET probe, followed by PET/CT imaging.

Recruitment Status: ...